Insulin Utopia

Trecroci, Daniel
December 2008
Diabetes Health;Dec2008/Jan2009, Vol. 17 Issue 6, p7
The article discusses the available insulins for every diabetes type. New insulins include a 24-hour insulin called Lantus which was approved in 2001, Levemir approved in 2005, fast-acting insulin called Apidra which was approved in 2004, Humalog, and NovoLog. These insulins were formulated to replicate the normal insulin profile according to the University of North Texas Health Science Center in Forth Worth, Texas. Insulin mixes which allow adjustment in the doses of injected insulin are also available.


Related Articles

  • insulin aspart.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin aspart, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin aspart has a faster rate of onset and offset of action than soluble insulin. Administration is by injection.

  • insulin lispro.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin lispro, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin lispro is relatively short-acting. Administration is by injection.

  • Insulin: A Voice for Choice. Teuscher, Arthur // Diabetes Health;Dec2007/Jan2008, Vol. 16 Issue 6, p18 

    The article discusses the dangers of hypoglycemic unawareness in diabetics who are taking human insulin. Human insulin came into use in the 1980s as a more physiological alternative to animal insulin, but some patients however reported a sudden loss of symptoms that had previously warned them...

  • A Case of Suppurative Granuloma Induced by Insulin Injection. Tanizaki, Hideaki; Matsumura, Vumi; Tokura, Yoshiki; Miyachi, Yoshiki; Kabashim, Kenji // Acta Dermato-Venereologica;2010, Vol. 90 Issue 5, p540 

    The article presents a case study of a 76-year-old woman with diabetes mellitus presenting with multiple deep-seated, slightly pruritic, symmetrical skin nodules on the flanks and thighs. She claimed that the lesion appeared two-three days after insulin injections. A skin biopsy of an...

  • YOUR DRUG WAS DISCONTINUED. Weil, Andrew // Time International (South Pacific Edition);5/8/2006, Issue 18, p139 

    The article presents information on issues related to the substitution of animal insulin with the synthetic one. The selling of animal insulin has been terminated in the U.S. from April 1, 2006, and synthetic human insulin, produced by recombinant-DNA technology, have entered the markets....

  • Insulin-producing neurospheres.  // PLoS Medicine;Apr2005, Vol. 2 Issue 4, p269 

    Discusses research being done on the differentiation of insulin-producing cells from human neural progenitor cells. Reference to a study by Seung Kim and colleagues published in this issue; Availability of recombinant insulin; Search for renewable sources of insulin-producing cells through...

  • An alternative insulin for diabetic dogs. Blake, Avi // Veterinary Medicine;Oct2012, Vol. 107 Issue 10, p430 

    The article discusses alternative insulin for dogs with diabetes mellitus in the U.S. It mentions that some of them suffering from the said disease are insufficiently controlled with neutral protamine Hagedorn (NPH) insulin which led veterinarians to search for a longer-acting insulin...

  • Excessive Islet NO Generation in Type 2 Diabetic GK Rats Coincides with Abnormal Hormone Secretion and Is Counteracted by GLP-1. Salehi, Albert; Abaraviciene, Sandra Meidute; Jimenez-Feltstrom, Javier; Östenson, Claes-Göran; Efendic, Suad; Lundquist, Ingmar // PLoS ONE;2008, Vol. 3 Issue 5, p1 

    Background: A distinctive feature of type 2 diabetes is inability of insulin-secreting β-cells to properly respond to elevated glucose eventually leading to β-cell failure. We have hypothesized that an abnormally increased NO production in the pancreatic islets might be an important factor...

  • Group action on insulin faces collapse. Dyer, Clare // BMJ: British Medical Journal (International Edition);3/27/93, Vol. 306 Issue 6881, p814 

    Reports the legal action of diabetic patients against the genetically engineered human insulin manufactured by pharmaceutical industry in Great Britain. Harmful effects of the product; Comparison of the biological effects between human and animal insulin; Factors contributing to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics